Cipla plans to divest consumer healthcare business
The OTC division recorded Rs 34.88 crore turnover or approximately 0.3 percent of the total consolidated income of Cipla for 2014-15
BS B2B Bureau B2B Connect | Mumbai
The divestment is expected to help Cipla participate in the attractive and growing over-the-counter (OTC) market. “This business requires a specialised FMCG kind of focus. A separate subsidiary would enable Cipla to attract right talent and provide the focus and attention required for this business,” added the company.
The OTC division recorded Rs 34.88 crore turnover or approximately 0.3% of the total consolidated income of Cipla for 2014-15. The net worth of OTC division as on March 31, 2015 was Rs 6.45 crores contributing 0.06% of the net worth of the company. The transaction is expected to be completed in the third quarter of FY 2015-16, subject to receipt of necessary approvals, Cipla added.
Also Read
OTC division recently launched its first product Nicotex, a gum which helps smokers quit the habit. This product is a switch from Cipla’s prescription business and has had a very successful launch in the South of the country, claims the company.
More From This Section
Don't miss the most important news and views of the day. Get them on our Telegram channel
First Published: Jul 10 2015 | 3:49 PM IST